SCHEMBL2715645

SCHEMBL2715645

Cc1cc(C(=O)NCc2cccc(OCC(F)(F)F)n2)cc(NC(=O)C(C)C)n1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.51
MAPT P10636 2/20 0.43
GSK3B P49841 2/20 0.43
SCN5A Q14524 1/20 0.39
HSD17B13 Q7Z5P4 1/20 0.39
EPHX2 P34913 2/20 0.38
WDR5 P61964 1/20 0.37
ADORA2A P29274 2/20 0.36
KCNH2 Q12809 1/20 0.35
KCNB1 Q14721 1/20 0.35
ADORA3 P0DMS8 2/20 0.35
ADORA1 P30542 1/20 0.35
ALDH1A1 P00352 2/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2713433 0.90 RIPK1 (0.41) SCN9ASCN5AHSD17B13EPHX2
SCHEMBL2713503 0.88 SCN9A (0.52) SCN9AMAPTGSK3BEPHX2ADORA3
SCHEMBL2719487 0.88 MEN1 (0.41) SCN9ASCN5AHSD17B13EPHX2WDR5
SCHEMBL2715903 0.88 GSK3B (0.57) SCN9AMAPTGSK3BEPHX2WDR5
SCHEMBL2717414 0.87 SCN9A (0.39) SCN9ASCN5AHSD17B13EPHX2WDR5
SCHEMBL2715345 0.86 SCN9A (0.52) SCN9AMAPTGSK3BEPHX2ADORA3
SCHEMBL2715988 0.86 SCN9A (0.51) SCN9AHSD17B13ADORA2AADORA3ADORA1
SCHEMBL2715665 0.85 SCN9A (0.51) SCN9AMAPTGSK3BSCN5AEPHX2
SCHEMBL2716841 0.84 SCN9A (0.52) SCN9AMAPTGSK3BEPHX2ADORA3
SCHEMBL2715900 0.84 SCN9A (0.51) SCN9AMAPTGSK3BEPHX2KCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP claimed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US claimed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US claimed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP claimed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO claimed
CN-106478497-B Arylamine derivatives as TTX-S blockers 拉夸里亚创药株式会社 2020-05-08 CN disclosed
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP disclosed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN2B, SCN1B, SCN2A SCN9A 31/4885MAPT 3185/4885GSK3B 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.